Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Park, Keunchil; B. Haura, Eric; B. Leighl, Natasha; Mitchell, Paul; A. Shu, Catherine; Girard, Nicolas; Viteri, Santiago; Han, Ji‐Youn; Kim, Sang‐We; Khoon Lee, Chee; K. Sabari, Joshua; I. Spira, Alexander; Yang, Tsung‐Ying; Kim, Dong‐Wan; Hyeong Lee, Ki; E. Sanborn, Rachel; Trigo, José; Goto, Kōichi; Lee, Jong‐Seok; Chih‐Hsin Yang, James; Govindan, Ramaswamy; Bauml, Joshua; Garrido, Pilar; Krebs, Matthew; L. Reckamp, Karen; Xie, John; C. Curtin, Joshua; Haddish‐Berhane, Nahor; Roshak, Amy; Millington, Dawn; Lorenzini, Patricia; Thayu, Meena; E. Knoblauch, Roland; Chul Cho, Byoung

doi:10.1200/jco.21.00662

Public

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Published in Journal of Clinical Oncology • Aug 2, 2021

Authors:

Keunchil Park

Eric B. Haura

Natasha B. Leighl

Abstract

PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell–directing activity, binds to each recept...

Subject

Medicine

Rash

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!